The 36-month beta value for CTXR is also noteworthy at 1.18. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for CTXR is 10.53M, and at present, short sellers hold a 12.81% of that float. The average trading volume of CTXR on July 09, 2025 was 2.49M shares.
CTXR) stock’s latest price update
The stock of Citius Pharmaceuticals Inc (NASDAQ: CTXR) has decreased by -8.08% when compared to last closing price of $2.11.Despite this, the company has seen a gain of 21.70% in its stock price over the last five trading days. prnewswire.com reported 2025-07-08 that CRANFORD, N.J. , July 8, 2025 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR) today announced that it has received formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that for 10 consecutive trading days, from June 20, 2025 to July 3, 2025, the closing bid price of the Company’s common stock was at $1.00 per share or greater, and accordingly, the Company regained compliance with Nasdaq Listing Rule 5550(a)(2).
CTXR’s Market Performance
Citius Pharmaceuticals Inc (CTXR) has experienced a 21.70% rise in stock performance for the past week, with a 126.10% rise in the past month, and a 90.64% rise in the past quarter. The volatility ratio for the week is 17.85%, and the volatility levels for the past 30 days are at 27.30% for CTXR. The simple moving average for the past 20 days is 42.85% for CTXR’s stock, with a -49.15% simple moving average for the past 200 days.
Analysts’ Opinion of CTXR
Many brokerage firms have already submitted their reports for CTXR stocks, with D. Boral Capital repeating the rating for CTXR by listing it as a “Buy.” The predicted price for CTXR in the upcoming period, according to D. Boral Capital is $9 based on the research report published on December 30, 2024 of the previous year 2024.
Maxim Group, on the other hand, stated in their research note that they expect to see CTXR reach a price target of $4. The rating they have provided for CTXR stocks is “Buy” according to the report published on November 30th, 2021.
CTXR Trading at 92.36% from the 50-Day Moving Average
After a stumble in the market that brought CTXR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.63% of loss for the given period.
Stock Fundamentals for CTXR
Current profitability levels for the company are sitting at:
- -203.46 for the present operating margin
- -0.34 for the gross margin
The net margin for Citius Pharmaceuticals Inc stands at -273.48. The total capital return value is set at -0.44. Equity return is now at value -60.06, with -39.63 for asset returns.
Based on Citius Pharmaceuticals Inc (CTXR), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -28.75.
Currently, EBITDA for the company is -38.64 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 144.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.37.
Conclusion
In summary, Citius Pharmaceuticals Inc (CTXR) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
